What does the evidence say about Nicotinamide Skin Barrier Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Nicotinamide Skin Barrier Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - 5-min exposures produced dose-dependent EIS decline with broad suppression of barrier and immune mediators (e.g., CXCL11, MCP4, and HNMT), 6-h exposure sustained skin barrier loss and associated inflammatory and remodeling programs. [Li M (2026); evidence level 4] - NAC/NAM reduced SDS-induced reactive oxygen species, cytotoxicity, and permeability in primary keratinocytes, and restored EIS values in ex vivo skin. [Li M (2026); evidence level 4] - Conclusion Short-term SDS exposure rapidly disrupts human skin barrier integrity through oxidative stress-driven suppression of structural/immune mediators and activation of stress/remodeling pathways. [Li M (2026); evidence level 4] - Background Epithelial barrier disruption is a hallmark of allergic skin diseases. [Li M (2026); evidence level 4] - In conclusion, integrating skin barrier measurements with omics and machine learning enabled the dissection of essential anti-inflammatory and keratinocyte differentiation mechanisms and genes of a strengthened skin barrier. [Pat Y (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.